Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusion [PDF]
BMC Cardiovascular Disorders, 2002 Background GPIIb/IIIa inhibitors abciximab and eptifibatide have been shown to inhibit platelet aggregation in ischemic heart disease. Our aim was to test the efficacy of abiciximab (Reo Pro) or eptifibatide (Integrilin) alone or in combination with ...
Giusti Andrea, Bertuglia Silva
doaj +5 more sources
Administration of eptifibatide as rescue therapy during mechanical thrombectomy in acute ischemic stroke [PDF]
Frontiers in NeurologyBackgroundThe success of the technical implementation of mechanical thrombectomy (MT) depends on many factors. Considering the experience of the interventional radiologist and the anatomical vascular differences of individual patients, it has technical ...
David Cernik +8 more
doaj +4 more sources
Impact of maintenance dose of eptifibatide in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention [PDF]
The Egyptian Heart Journal, 2023 Background ST-segment elevation myocardial infarction (STEMI) is usually caused by a rupture in the atherosclerotic plaque, followed by platelet aggregation which ultimately leads to acute coronary artery occlusion.
Rozita Jalalian +5 more
doaj +2 more sources
Local Intracoronary Eptifibatide versus Mechanical Aspiration in Patients with Acute ST-Elevation Myocardial Infarction [PDF]
International Journal of Vascular Medicine, 2014 Objectives. We compared local delivery of intracoronary eptifibatide via perfusion catheter to thrombus aspiration in primary PCI. Background. Perfusion catheter increases local concentration of the drugs at the culprit site and prolongs their residency ...
Mohamed A. Hamza +3 more
doaj +2 more sources
A rare case of eptifibatide-induced thrombocytopenia [PDF]
Journal of Community Hospital Internal Medicine Perspectives, 2021 Eptifibatide is a glycoprotein (GP) IIb/IIIa receptor antagonist, used for the treatment of acute coronary syndrome with high-risk features or ongoing ischemia.
Khalil Kamar +4 more
doaj +2 more sources
Profound thrombocytopenia after primary exposure to eptifibatide
Drug, Healthcare and Patient Safety, 2010 Nicholas B Norgard, Brian T BadgleyUniversity at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USAAbstract: Eptifibatide is a glycoprotein IIb/IIIa receptor antagonist used to reduce the incidence of ischemic events in patients ...
Nicholas B Norgard, Brian T Badgley
doaj +3 more sources
Protective effects of combined eptifibatide and ticagrelor in patients with unstable angina undergoing percutaneous coronary intervention: a single-center experience [PDF]
BMC Cardiovascular DisordersBackground We evaluated the safety and effectiveness of combined eptifibatide and ticagrelor in patients with unstable angina pectoris undergoing percutaneous coronary intervention (PCI).
Shangsong Shi +4 more
doaj +2 more sources
Immediate outcomes of eptifibatide therapy during intracoronary stent implantation
Advanced Biomedical Research, 2016 Background: The objective of the present study was to assess the major immediate outcomes of eptifibatide therapy during intracoronary stent implantation.
Hooman Shariati +4 more
doaj +2 more sources
Comparative Effects of Glenzocimab and Eptifibatide on Bleeding Severity in 2 Mouse Models of Intracranial Hemorrhage [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Antiplatelet drugs represent potential candidates for protecting the penumbral microcirculation during cerebral ischemia and improving the benefits of arterial recanalization in ischemic stroke.
Sébastien Dupont +18 more
doaj +2 more sources
A woman with eptifibatide (integrilin)‐induced thrombocytopenia following treatment of a clot in her coronary artery: A case report and literature review [PDF]
Clinical Case ReportsEptifibatide, a GPIIb/IIIa receptor inhibitor, has shown its efficacy and safety in patients with high clot burden in their coronary vessels. It is widely used in patients with this condition.
Morteza Safi +4 more
doaj +2 more sources